Bellerophon Therapeutics Inc (BLPH)

NASDAQ
4.000
-0.140(-3.38%)
Pre Market
3.960
-0.040(-1.00%)
- Real-time Data
  • Volume:
    35,429
  • Bid/Ask:
    3.960/4.720
  • Day's Range:
    3.970 - 4.198

BLPH Overview

Prev. Close
4
Day's Range
3.97-4.198
Revenue
-
Open
4.16
52 wk Range
3.79-12.74
EPS
-2.76
Volume
35,429
Market Cap
38.03M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
177,800
P/E Ratio
-
Beta
-0.53
1-Year Change
-67.9%
Shares Outstanding
9,506,419
Next Earnings Date
Aug 11, 2021
What is your sentiment on Bellerophon Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Bellerophon Therapeutics Inc News

Bellerophon Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellStrong Sell
Technical IndicatorsNeutralStrong SellStrong SellStrong SellStrong Sell
SummaryNeutralStrong SellStrong SellStrong SellStrong Sell

Bellerophon Therapeutics Inc Company Profile

Bellerophon Therapeutics Inc Company Profile

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.